X

Trial Profile

Multicenter Open Label Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Elacestrant (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

25 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jan 2025.
25 Jul 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2024.
10 May 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com